TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Acta Oncologica

Volumn 53, Issue 10, 2014, Pages 1347-1355

  Eikesdal, Hans P ^a,b   Knappskog, Stian ^a   Aas, Turid ^b   Lonning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOMYCIN; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC AGENT; MITOMYCIN DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LOCALLY ADVANCED BREAST CANCER; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; SHORT TERM SURVIVAL; AXILLA; BREAST NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; TIME FACTOR; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MITOMYCINS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TIME FACTORS;

EID: 84911932667     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.922215     Document Type: Article

References (28)

1. Haagensen CD, Stout AP. Carcinoma of the breast: II. Criteria of operability. Ann Surg 1943; 118: 859-70.
2. Rubens RD, Armitage P, Winter PJ, Tong D, Hayward JL. Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer 1977; 13: 805-11.
3. Swain SM, Sorace RA, Bagley CS, Danforth DN, Jr., Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987; 47: 3889-94.
4. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988; 62: 2507-16.
5. Bedwinek J, Rao DV, Perez C, Lee J, Fineberg B. Stage III and localized stage IV breast cancer: Irradiation alone vs irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982; 8: 31-6.
6. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N, Baum M. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 1993; 29A: 1796-9.
7. Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL. Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer 1980; 16: 351-6.
8. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-4.
9. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with dox-orubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505-12.
10. Nylen U, Baral E, Svane G, Rutqvist LE. Weekly doxorubicin in the treatment of metastatic breast carcinoma. Acta Oncol 1989; 28: 515-7.
11. Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, et al. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47-51.
12. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-8.
13. Gundersen S, Kvinnsland S, Klepp O, Lund E, Hannisdal E, Host H. Chemotherapy with or without high-dose medroxy-progesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. Eur J Cancer 1992; 28: 390-4.
14. Mattsson W, von Eyben F, Hallsten L, Bjelkengren G. A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer 1982; 49: 217-20.
15. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-34.
16. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157-67.
17. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): A randomised phase 3 trial. Lancet Oncol 2011; 12: 527-39.
18. Thorsen T. Occupied and unoccupied oestradiol receptor in human breast tumour cytosol. J Steroid Biochem 1980; 13: 405-8.
19. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
20. Dikomey E, Borgmann K, Peacock J, Jung H. Why recent studies relating normal tissue response to individual radio-sensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys 2003; 56: 1194-200.
21. Peters LJ. The ESTRO Regaud lecture. Inherent radiosensi-tivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 1990; 17: 177-90.
22. West CM. Invited review: Intrinsic radiosensitivity as a predictor of patient response to radiotherapy. Br J Radiol 1995; 68: 827-37.
23. Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S, et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 2012; 14: R47.
24. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overex-pression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-6.
25. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3: e3062.
26. Lehmann-Che J, Andre F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, et al. Cyclophosphamide dose inten-sification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010; 15: 246-52.
27. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 2011; 6: e19249.
28. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-6.